High-dose prophylactic anticoagulation or therapeutic anticoagulation reduced de novo thrombosis in patients with hypoxemic COVID-19 pneumonia, based on data from 334 adults. Patients with hypoxemic ...

Prophylactic anticoagulation to prevent venous thromboembolism (VTE) was associated with reduced 60-day mortality in patients with COVID-19 who were ill enough to require hospitalization, a new report ...

Phenotype-guided dosing strategies can increase the proportion of patients with hematologic malignancies who achieve a therapeutic drug concentration of prophylactic voriconazole, according to results ...

Therapeutic-dose anticoagulation with heparins reduced 28-day mortality compared with prophylactic doses in patients hospitalized with COVID-19. Higher-dose anticoagulation was associated with a ...

The anti-coagulant heparin reduces the likelihood of death from COVID-19 by 78% when administered in therapeutic doses to patients with signs of respiratory failure on admission to hospital, according ...

Immunological recovery in children with ALL at the end of intensive therapy, at the completion of therapy, and up to one year off therapy. A follow-up study No significant financial relationships to ...

A new study demonstrated that trekkers and climbers taking a lower dose of acetazolamide (62.5 mg twice daily) were no more likely to develop acute mountain sickness (AMS) symptoms than those who took ...

Results for the first 10 patients offer promising signs for giving patients with multiple myeloma a prophylactic dose of tocilizumab before they are treated with the bispecifc antibody teclistamab.